Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Counsyl | RCV000669292 | SCV000794031 | uncertain significance | GNE myopathy | 2017-11-14 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001349759 | SCV001544119 | uncertain significance | GNE myopathy; Sialuria | 2024-04-16 | criteria provided, single submitter | clinical testing | This sequence change replaces methionine, which is neutral and non-polar, with valine, which is neutral and non-polar, at codon 483 of the GNE protein (p.Met483Val). This variant is present in population databases (rs746051210, gnomAD 0.004%). This variant has not been reported in the literature in individuals affected with GNE-related conditions. ClinVar contains an entry for this variant (Variation ID: 553775). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) has been performed at Invitae for this missense variant, however the output from this modeling did not meet the statistical confidence thresholds required to predict the impact of this variant on GNE protein function. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Natera, |
RCV000669292 | SCV002075645 | uncertain significance | GNE myopathy | 2019-10-28 | no assertion criteria provided | clinical testing |